Cypherpunk Technologies Inc.

CYPH · Nasdaq · United States

Share price · CYPH

$1.75+0.94 (+117.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 9.4M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CYPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026-19.7%
  2. 18 Sep 2026+17.3%
  3. 17 Sep 2026+25.8%

    Nothing announced by CYPH that day or the session before.

  4. 3 Sep 2026+35.1%
  5. 19 Aug 2026+32.9%
  6. 15 Jun 2026+25.0%
  7. 8 Jun 2026+36.5%
  8. 5 Jun 2026-47.1%

    Nothing announced by CYPH that day or the session before.

  9. 4 Jun 2026-16.8%

    Nothing announced by CYPH that day or the session before.

  10. 2 Jun 2026+13.3%

Share of unusual movement by asset

For each asset, the share of CYPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—82%
Sessions with no dated event—18%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
DKK1 (Dickkopf-1)Monoclonal antibody
Colorectal Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.2M$7.6M—-$2.7M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$0.2M$6.7M$77M-$3.4M operating cash flowreport ↗
2025-Q3—$1.3M$9.7M$3.3M-$8.3M operating cash flowreport ↗
2025-Q2—$11M$18M$17M-$14M operating cash flowreport ↗
2025-Q1—$13M$33M$15M-$14M operating cash flowreport ↗
2024-Q3—$15M$63M$18M-$16M operating cash flowreport ↗
2024-Q2—$18M$78M$20M-$14M operating cash flowreport ↗
2024-Q1—$11M$55M$14M-$16M operating cash flowreport ↗
2023-Q3—$12M$81M$14M-$10M operating cash flowreport ↗
2023-Q2—$11M$91M$13M-$10M operating cash flowreport ↗
2023-Q1—$39M$102M$42M-$13M operating cash flowreport ↗
2022-Q3—$12M$78M$15M-$12M operating cash flowreport ↗
2022-Q2—$14M$91M$17M-$12M operating cash flowreport ↗
2022-Q1—$7.8M$103M$10M-$12M operating cash flowreport ↗
2021-Q3$0.4M$10M$125M$11M-$8.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$26M$14M—-$44M operating cash flowreport ↗

Leap Therapeutics, Inc. reported R&D spend of $25.67M, down 55.1% YoY, cash and equivalents of $14.04M, and net income of $4.82M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$57M$47M$17M-$60M operating cash flowreport ↗
2023-FY—$73M$71M$20M-$44M operating cash flowreport ↗
2022-FY—$45M$66M$14M-$49M operating cash flowreport ↗
2021-FY$1.5M$32M$115M$10M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($932K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-12Winklevoss Capital Fund, LLC; Winklevoss Treasury Investments, LLC; Winklevoss Tyler Howard; Winklevoss Cameron Howard; Winklevoss Capital Management, LLC · 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOption exercise4,938,801$0.00$5KForm 4
2026-10-12McEvoy William Patrick III · director, Chief Investment Officer, 10% ownerOption exercise4,938,801$0.00$5KForm 4
2026-10-12Winklevoss Capital Fund, LLC; Winklevoss Treasury Investments, LLC; Winklevoss Tyler Howard; Winklevoss Cameron Howard; Winklevoss Capital Management, LLC · 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOption exercise (derivative)4,938,801$0.52$2.6MForm 4
2026-10-12McEvoy William Patrick III · director, Chief Investment Officer, 10% ownerOption exercise (derivative)4,938,801$0.52$2.6MForm 4
2026-09-25Oei Khing Djien · directorOpen-market sale168,750$3.92$662KForm 4
2026-09-23Martin Patricia A. · directorOpen-market sale50,000$3.86$193KForm 4
2026-08-26Dietz Thomas John · directorOpen-market sale20,000$1.72$34KForm 4
2026-08-21Zhang Kevin · Head of MiningAward / grant (derivative)2,000,000——Form 4